ZMA CLEAR SODIUM SULFACETAMIDE 9% AND SULFUR 4.5%- sulfacetamide sodium and sulfur suspension

ZMA CLEAR Sodium Sulfacetamide 9% and Sulfur 4.5% by

Drug Labeling and Warnings

ZMA CLEAR Sodium Sulfacetamide 9% and Sulfur 4.5% by is a Prescription medication manufactured, distributed, or labeled by Gabar Health Sciences Corp.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

SPL UNCLASSIFIED SECTION

Rx Only

DESCRIPTION

DESCRIPTION

Sodium Sulfacetamide is a sulfonamide with antibacterial with antibacterial activity while sulfur acts as a keratolytic agent. Chemically, Sodium Sulfacetamide is N-[(4-aminophenyl) sulfony]-acetamide, monosodium salt, monohydrate. The structural formula is:

Each mL of Sodium Sulfacetamide 9% & Sulfur 4.5% Suspension contains 90 mg of sodium sulfacetamide and 45 mg of sulfur in a formulation consisting of: aloe vera, fragrance, butylated hydroxytoluene, cetyl alcohol, disodium EDTA, disodium oleamido MEA sulfosuccinate, glyceryl stearate (and) PEG-100 stearate, green tea extract, magnesium aluminum silicate, methylparaben, propylparaben, purified water, sodium cocoyl isethionate, sodium methyl cocoyl tau rate, sodium thiosulfate, stearyl alcohol, and xanthan gum.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY

The most widely accepted mechanism of action of sulfonamides in the Woods-Fildes theory which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact skin has not been determined, Sodium Sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. The biological half-life has variously been reported as 7 to 12.8 hours. The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.

INDICATIONS & USAGE

INDICATIONS

Zma Clear™ (Sodium Sulfacetamide 9% & Sulfur 4.5% Suspension) is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

CONTRAINDICATIONS

CONTRAINDICATIONS

Zma Clear™ Sodium Sulfacetamide 9% & Sulfur 4.5% suspension is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur, or any other component of this preparation. Zma Clear™ is not to be used by patients with kidney disease.

WARNINGS

WARNINGS

Although rare, sensitivity to Sodium Sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice, and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.

FOR EXTERNAL USE ONLY. Keep away from eyes. Keep out of reach of children. Keep container tightly closed.

PRECAUTIONS

General 

If irritation develops, use of this product should be discontinued and appropriate therapy instituted. Patients should be very carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but Sodium Sulfacetamide and Sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.

Information for Patients

Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. If excessive irritation develops, discontinue use and consult your physician.

Carcinogenesis, Mutagenesis and Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential.

Pregnancy

Category C

Animal reproduction studies have not been conducted with Sodium Sulfacetamide 9% & Sulfur 4.5% Suspension. It is also not known whether Sodium Sulfactamide 9% & Sulfur 4.5% Suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Sulfacetamide 9% & Sulfur 4.5% Suspension is administered to a nursing woman.

PEDIATRIC USE

Pediatric Use

Safety and effectiveness in children under the age of 12 has not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS

Although rare, sodium sulfacetamide may cause local irritation.

DOSAGE & ADMINISTRATION

DOSAGE AND ADMINISTRATION

Apply Sodium Sulfacetamide 9% & Sulfur 4.5% Suspension once or twice daily to affected areas or as directed by your physician. Wet skin and liberally apply to areas to be cleansed. Massage gently into skin for 10-20 seconds, working into a lather. Rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing off Sodium Sulfacetamide 9% & Sulfur 4.5% Suspension sooner or using less often.

HOW SUPPLIED

HOW SUPPLIED

Zma Clear™ Sodium Sulfacetamide 9% & Sulfur 4.5% suspension is available in an 8 oz (237 mL) bottle, NDC: 82429-106-08.

STORAGE AND HANDLING

STORAGE

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F).  Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F), however such exposure should be minimized.  Protect from freezing.

KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN

SPL UNCLASSIFIED SECTION

Manufactured by:

Gabar Health Sciences, Corp.
Atlanta, Georgia 30354

PRINCIPAL DISPLAY PANEL - 8 oz (237 mL) Bottle Label

NDC: 82429-106-08

Rx only

For topical use only

Not ophthalmic use

Sodium Sulfacetamide 9% & Sulfur 4.5% Suspension

Gabar Health Sciences Corp.

Net WT. 8oz. (237 mL)

INGREDIENTS AND APPEARANCE

ZMA CLEAR SODIUM SULFACETAMIDE 9% AND SULFUR 4.5% 
sulfacetamide sodium and sulfur suspension

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC: 82429-106
Route of Administration	TOPICAL

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
SULFACETAMIDE SODIUM (UNII: 4NRT660KJQ) (SULFACETAMIDE - UNII:4965G3J0F5)	SULFACETAMIDE SODIUM	90 mg  in 1 mL
SULFUR (UNII: 70FD1KFU70) (SULFUR - UNII:70FD1KFU70)	SULFUR	45 mg  in 1 mL

Inactive Ingredients
Ingredient Name	Strength
ALOE VERA LEAF (UNII: ZY81Z83H0X)
BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)
CETYL ALCOHOL (UNII: 936JST6JCN)
EDETATE DISODIUM (UNII: 7FLD91C86K)
DISODIUM OLEAMIDO MEA-SULFOSUCCINATE (UNII: 5M1101WGSY)
GLYCERIN (UNII: PDC6A3C0OX)
GLYCERYL MONOSTEARATE (UNII: 230OU9XXE4)
PEG-100 STEARATE (UNII: YD01N1999R)
GREEN TEA LEAF (UNII: W2ZU1RY8B0)
MAGNESIUM ALUMINUM SILICATE (UNII: 6M3P64V0NC)
METHYLPARABEN (UNII: A2I8C7HI9T)
PROPYLPARABEN (UNII: Z8IX2SC1OH)
WATER (UNII: 059QF0KO0R)
SODIUM COCOYL ISETHIONATE (UNII: 518XTE8493)
SODIUM METHYL COCOYL TAURATE (UNII: JVL98CG53G)
SODIUM THIOSULFATE (UNII: HX1032V43M)
STEARYL ALCOHOL (UNII: 2KR89I4H1Y)
XANTHAN GUM (UNII: TTV12P4NEE)

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC: 82429-106-08	1 in 1 CARTON	03/16/2023
1		237 mL in 1 BOTTLE; Type 0: Not a Combination Product

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		03/16/2023

Labeler - Gabar Health Sciences Corp. (118401847)

Registrant - Gabar Health Sciences Corp. (118401847)